Multicenter, double-blind, placebo-controlled trial of triamcinolone acetonide nasal aerosol in the treatment of perennial allergic rhinitis.

Abstract

In a double-blind study involving 205 patients with perennial allergic rhinitis, statistically significantly greater symptomatic improvements were evident following the administration of 200 micrograms/day triamcinolone acetonide aerosol than following placebo. These improvements were evident as early as week 1 and were sustained throughout the 12-week study. They were accompanied by greater reductions in nasal eosinophils. Triamcinolone acetonide aerosol was well tolerated and had no effect on serum cortisol levels.

• Authors: S Spector, E Bronsky, P Chervinsky, G Lotner, J Koepke, J Selner, D Pearlman, D Tinkelman, S Weakley, V Alderfer
• Journal: Annals of allergy (Ann Allergy) Vol. 64 Issue 3 Pg. 300-5 (Mar 1990) ISSN: 0003-4738 [Print] United States
• PMID: 2178497 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Aerosols
• Placebos
• Triamcinolone Acetonide

Topics

• Administration, Intranasal
• Aerosols
• Double-Blind Method
• Humans
• Multicenter Studies as Topic
• Placebos
• Rhinitis, Allergic, Perennial (drug therapy, physiopathology)
• Triamcinolone Acetonide (adverse effects, therapeutic use)